An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Eli Lilly has reduced the prices of certain Zepbound ... In late February, the FDA delisted semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies have 60 or 90 days ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...

Like many pharma stocks, Eli Lilly (NYSE: LLY ... commercialized as Ozempic and Wegovy. These drugs all have produced impressive results in clinical trials and in the real world, and that has ...